Skip to main content
PMC home page
Transactions of the American Clinical and Climatological Association logoLink to Transactions of the American Clinical and Climatological Association
. 2004;115:289–303.

HIV Evolution and Escape.

Douglas D Richman 1, Susan J Little 1, Davey M Smith 1, Terri Wrin 1, Christos Petropoulos 1, Joseph K Wong 1
PMCID: PMC2263778  PMID: 17060974

Abstract

Human immunodeficiency virus (HIV) exemplifies the principles of Darwinian evolution with a telescoped chronology. Because of its high mutation rate and remarkably high rates of replication, evolution can be appreciated over periods of days in contrast to the durations conceived of by Darwin. Certain selective pressures that drive the evolution of HIV include chemotherapy, anatomic compartmentalization and the immune response. Examples of these selective forces on HIV evolution are described.

Full text

PDF
291

Images in this article

294Fig. 5
on p.294

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burton D. R. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018–10023. doi: 10.1073/pnas.94.19.10018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coombs Robert W., Reichelderfer Patricia S., Landay Alan L. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003 Mar 7;17(4):455–480. doi: 10.1097/00002030-200303070-00001. [DOI] [PubMed] [Google Scholar]
  3. Dezzutti C. S., Guenthner P. C., Cummins J. E., Jr, Cabrera T., Marshall J. H., Dillberger A., Lal R. B. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis. 2001 Mar 13;183(8):1204–1213. doi: 10.1086/319676. [DOI] [PubMed] [Google Scholar]
  4. Drake J. W. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A. 1993 May 1;90(9):4171–4175. doi: 10.1073/pnas.90.9.4171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Edinger A. L., Mankowski J. L., Doranz B. J., Margulies B. J., Lee B., Rucker J., Sharron M., Hoffman T. L., Berson J. F., Zink M. C. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14742–14747. doi: 10.1073/pnas.94.26.14742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Edwards T. G., Hoffman T. L., Baribaud F., Wyss S., LaBranche C. C., Romano J., Adkinson J., Sharron M., Hoxie J. A., Doms R. W. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol. 2001 Jun;75(11):5230–5239. doi: 10.1128/JVI.75.11.5230-5239.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Epstein L. G., Kuiken C., Blumberg B. M., Hartman S., Sharer L. R., Clement M., Goudsmit J. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology. 1991 Feb;180(2):583–590. doi: 10.1016/0042-6822(91)90072-j. [DOI] [PubMed] [Google Scholar]
  8. FRANCIS T., Jr Influenza: the new acquayantance. Ann Intern Med. 1953 Aug;39(2):203–221. doi: 10.7326/0003-4819-39-2-203. [DOI] [PubMed] [Google Scholar]
  9. Fazekas de St Groth, Webster R. G. Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med. 1966 Sep 1;124(3):331–345. doi: 10.1084/jem.124.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  11. Geijtenbeek T. B., Kwon D. S., Torensma R., van Vliet S. J., van Duijnhoven G. C., Middel J., Cornelissen I. L., Nottet H. S., KewalRamani V. N., Littman D. R. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000 Mar 3;100(5):587–597. doi: 10.1016/s0092-8674(00)80694-7. [DOI] [PubMed] [Google Scholar]
  12. Gorry Paul R., Taylor Joann, Holm Geoffrey H., Mehle Andrew, Morgan Tom, Cayabyab Mark, Farzan Michael, Wang Hui, Bell Jeanne E., Kunstman Kevin. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol. 2002 Jun;76(12):6277–6292. doi: 10.1128/JVI.76.12.6277-6292.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gulick R. M., Mellors J. W., Havlir D., Eron J. J., Gonzalez C., McMahon D., Richman D. D., Valentine F. T., Jonas L., Meibohm A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997 Sep 11;337(11):734–739. doi: 10.1056/NEJM199709113371102. [DOI] [PubMed] [Google Scholar]
  14. Gupta P., Leroux C., Patterson B. K., Kingsley L., Rinaldo C., Ding M., Chen Y., Kulka K., Buchanan W., McKeon B. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral Quasi species between blood and semen. J Infect Dis. 2000 Jun 29;182(1):79–87. doi: 10.1086/315644. [DOI] [PubMed] [Google Scholar]
  15. Günthard H. F., Wong J. K., Ignacio C. C., Guatelli J. C., Riggs N. L., Havlir D. V., Richman D. D. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998 Mar;72(3):2422–2428. doi: 10.1128/jvi.72.3.2422-2428.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Haggerty S., Stevenson M. Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals. Viral Immunol. 1991 Summer;4(2):123–131. doi: 10.1089/vim.1991.4.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hirsch M. S., Brun-Vézinet F., D'Aquila R. T., Hammer S. M., Johnson V. A., Kuritzkes D. R., Loveday C., Mellors J. W., Clotet B., Conway B. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000 May 10;283(18):2417–2426. doi: 10.1001/jama.283.18.2417. [DOI] [PubMed] [Google Scholar]
  18. Hirsch M. S., Conway B., D'Aquila R. T., Johnson V. A., Brun-Vézinet F., Clotet B., Demeter L. M., Hammer S. M., Jacobsen D. M., Kuritzkes D. R. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998 Jun 24;279(24):1984–1991. doi: 10.1001/jama.279.24.1984. [DOI] [PubMed] [Google Scholar]
  19. Korber B. T., Kunstman K. J., Patterson B. K., Furtado M., McEvilly M. M., Levy R., Wolinsky S. M. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol. 1994 Nov;68(11):7467–7481. doi: 10.1128/jvi.68.11.7467-7481.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Korber B., Muldoon M., Theiler J., Gao F., Gupta R., Lapedes A., Hahn B. H., Wolinsky S., Bhattacharya T. Timing the ancestor of the HIV-1 pandemic strains. Science. 2000 Jun 9;288(5472):1789–1796. doi: 10.1126/science.288.5472.1789. [DOI] [PubMed] [Google Scholar]
  21. Krieger J. N., Nirapathpongporn A., Chaiyaporn M., Peterson G., Nikolaeva I., Akridge R., Ross S. O., Coombs R. W. Vasectomy and human immunodeficiency virus type 1 in semen. J Urol. 1998 Mar;159(3):820–826. [PubMed] [Google Scholar]
  22. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  23. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  24. Larsen R. A., Bozzette S., McCutchan J. A., Chiu J., Leal M. A., Richman D. D. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med. 1989 Jul 15;111(2):125–128. doi: 10.7326/0003-4819-111-2-125. [DOI] [PubMed] [Google Scholar]
  25. Little Susan J., Holte Sarah, Routy Jean-Pierre, Daar Eric S., Markowitz Marty, Collier Ann C., Koup Richard A., Mellors John W., Connick Elizabeth, Conway Brian. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002 Aug 8;347(6):385–394. doi: 10.1056/NEJMoa013552. [DOI] [PubMed] [Google Scholar]
  26. Mansky L. M., Temin H. M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995 Aug;69(8):5087–5094. doi: 10.1128/jvi.69.8.5087-5094.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Moutouh L., Corbeil J., Richman D. D. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6106–6111. doi: 10.1073/pnas.93.12.6106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Palumbi S. R. Humans as the world's greatest evolutionary force. Science. 2001 Sep 7;293(5536):1786–1790. doi: 10.1126/science.293.5536.1786. [DOI] [PubMed] [Google Scholar]
  29. Pang S., Vinters H. V., Akashi T., O'Brien W. A., Chen I. S. HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease. J Acquir Immune Defic Syndr. 1991;4(11):1082–1092. [PubMed] [Google Scholar]
  30. Paranjpe Shirish, Craigo Jodi, Patterson Bruce, Ding Ming, Barroso Paulo, Harrison Lee, Montelaro Ronald, Gupta Phalguni. Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues. AIDS Res Hum Retroviruses. 2002 Nov 20;18(17):1271–1280. doi: 10.1089/088922202320886316. [DOI] [PubMed] [Google Scholar]
  31. Parren P. W., Burton D. R. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol. 2001;77:195–262. doi: 10.1016/S0065-2776(01)77018-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586. doi: 10.1126/science.271.5255.1582. [DOI] [PubMed] [Google Scholar]
  33. Petropoulos C. J., Parkin N. T., Limoli K. L., Lie Y. S., Wrin T., Huang W., Tian H., Smith D., Winslow G. A., Capon D. J. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Apr;44(4):920–928. doi: 10.1128/aac.44.4.920-928.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pillai Satish, Good Benjamin, Richman Douglas, Corbeil Jacques. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses. 2003 Feb;19(2):145–149. doi: 10.1089/088922203762688658. [DOI] [PubMed] [Google Scholar]
  35. Piot P., Bartos M., Ghys P. D., Walker N., Schwartländer B. The global impact of HIV/AIDS. Nature. 2001 Apr 19;410(6831):968–973. doi: 10.1038/35073639. [DOI] [PubMed] [Google Scholar]
  36. Poss M., Rodrigo A. G., Gosink J. J., Learn G. H., de Vange Panteleeff D., Martin H. L., Jr, Bwayo J., Kreiss J. K., Overbaugh J. Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1. J Virol. 1998 Oct;72(10):8240–8251. doi: 10.1128/jvi.72.10.8240-8251.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Power C., McArthur J. C., Johnson R. T., Griffin D. E., Glass J. D., Perryman S., Chesebro B. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol. 1994 Jul;68(7):4643–4649. doi: 10.1128/jvi.68.7.4643-4649.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Puffer Bridget A., Pöhlmann Stefan, Edinger Aimee L., Carlin Dan, Sanchez Melissa D., Reitter Julie, Watry Debbie D., Fox Howard S., Desrosiers Ronald C., Doms Robert W. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol. 2002 Mar;76(6):2595–2605. doi: 10.1128/JVI.76.6.2595-2605.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Reddy Y. Sunila, Kashuba Angela, Gerber John, Miller Veronica, Rondtable Participants, Forum for Collaborative HIV Research Roundtable report: importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res Hum Retroviruses. 2003 Mar;19(3):167–176. doi: 10.1089/088922203763315669. [DOI] [PubMed] [Google Scholar]
  40. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  41. Richman D. D., Grimes J. M., Lagakos S. W. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3(8):743–746. [PubMed] [Google Scholar]
  42. Richman D. D. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res. 1996 Jan;29(1):31–33. doi: 10.1016/0166-3542(95)00911-6. [DOI] [PubMed] [Google Scholar]
  43. Richman Douglas D., Wrin Terri, Little Susan J., Petropoulos Christos J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003 Mar 18;100(7):4144–4149. doi: 10.1073/pnas.0630530100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Srinivasakumar N., Chazal N., Helga-Maria C., Prasad S., Hammarskjöld M. L., Rekosh D. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol. 1997 Aug;71(8):5841–5848. doi: 10.1128/jvi.71.8.5841-5848.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Venturi G., Catucci M., Romano L., Corsi P., Leoncini F., Valensin P. E., Zazzi M. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis. 2000 Feb;181(2):740–745. doi: 10.1086/315249. [DOI] [PubMed] [Google Scholar]
  46. Xu C., Politch J. A., Tucker L., Mayer K. H., Seage G. R., 3rd, Anderson D. J. Factors associated with increased levels of human immunodeficiency virus type 1 DNA in semen. J Infect Dis. 1997 Oct;176(4):941–947. doi: 10.1086/516539. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Clinical and Climatological Association are provided here courtesy of American Clinical and Climatological Association

RESOURCES